### Analysis

Merck & Co., Inc. reported strong Q3 2018 earnings, with total revenues up 5% year-over-year to $10.8 billion. The company’s Human Health segment, led by KEYTRUDA, saw significant growth, and the Animal Health business also performed well. The company’s dividend and share repurchase programs were increased, reflecting confidence in its future growth prospects.

Key points:
- **Financial Performance**: Merck reported solid financial performance, with revenues growing 5% year-over-year and EPS increasing 8%.
- **KEYTRUDA**: The company highlighted the continued strong performance of KEYTRUDA, with sales up 24% year-over-year. The drug continues to lead the I-O field with its breadth and depth of indications across multiple tumor types.
- **GARDASIL**: The vaccine showed strong demand worldwide, with sales of over $1 billion in the quarter.
- **Pipeline and Business Development**: Merck continues to invest heavily in its pipeline and business development, with a strong focus on oncology and vaccines. The company’s capital allocation strategy includes significant spending on R&D and manufacturing capacity.
- **Outlook**: The company expects revenues to be between $42.1 billion and $42.7 billion for the full year, with EPS expected to be between $4.30 and $4.36.

### Conclusion

Given Merck's strong financial performance, the continued growth of KEYTRUDA, and the company's robust pipeline, the stock is likely to see positive momentum in the short term. The dividend increase and share repurchase program also indicate management's confidence in the company's long-term prospects. The stock is expected to rally in the next 1-2 weeks.

**Rating: 2**